XZP-5955

N/A

Report date: 2024/10/22 15:58:57
NME

Base Information

Drug NameXZP-5955
Drug Alias NameXZP-5955XZP-P5955
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProto-oncogene tyrosine-protein kinase ROS inhibitorsTropomyosin-related kinase inhibitors
TargetsProto-oncogene tyrosine-protein kinase ROSTropomyosin-related kinase
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesXuanzhu (Shijiazhuang) Biotechnology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesXuanzhu (Shijiazhuang) Biotechnology Co LtdXuanzhu (HK) Biopharmaceutical Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A